Tag: Hikma Pharmaceuticals

June 15, 2020 Off

Hikma, Sun Pharma in licensing agreement for Ilumya for the MENA region

By Dino Mustafić

Hikma Pharmaceuticals and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), the world’s fourth largest specialty generic pharmaceutical company, announced today that they have entered into an exclusive licensing and distribution agreement for Ilumya, an innovative biologic product, for the Middle East and North Africa (MENA) region.

November 27, 2019 Off

HIkma responds to FDA about GSK’s Advair Diskus

By Dino Mustafić

Hikma has submitted to the US Food and Drug Administration (FDA) its response to deficiencies in its abbreviated new drug application (ANDA) for a generic version of GlaxoSmithKline’s Advair Diskus® (fluticasone propionate and salmeterol inhalation powder).

May 17, 2017 Off

Hikma launches Ethacrynic Acid Tablets in the US market

By Dino Mustafić

Hikma Pharmaceuticals’s US subsidiary West-Ward Pharmaceuticals has launched Ethacrynic Acid Tablets USP in 25mg strength, the generic equivalent to Edecrin (ethacrynic acid) for the treatment of edema when an agent with greater diuretic potential than those commonly employed is required.